Avalo Therapeutics (AVTX) Non Operating Investment Income (2019 - 2020)
Avalo Therapeutics (AVTX) posted Non Operating Investment Income of -$1.9 million for Q2 2020, down 126.44% on a QoQ basis from $7.1 million in Q1 2020.
Avalo Therapeutics (AVTX) Non Operating Investment Income (2019 - 2020) Analysis & Trends
Avalo Therapeutics' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at -$1.9 million for Q2 2020.
- Quarterly Non Operating Investment Income changed N/A year-over-year to -$1.9 million in Q2 2020, while the trailing twelve-month figure through Mar 2021 was -$1.9 million (down 126.24% YoY) and the FY2020 annual result came in at $5.2 million, up 9556.6% from the prior year.
- Non Operating Investment Income was -$1.9 million for Q2 2020 at Avalo Therapeutics, down from $7.1 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $7.1 million in Q1 2020 and bottomed at -$1.9 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Avalo Therapeutics | 395.30 Mn | 338.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -1.87 Mn |
| Jun 30, 2020 | -1.87 Mn |
| Mar 31, 2020 | 7.08 Mn |
| Mar 31, 2020 | 7.08 Mn |
| Dec 31, 2019 | 53,932.00 |
| Dec 31, 2019 | 53,932.00 |